Skip to main content
Free research Free research Free target review with research home and workspace preview
Quick search ChEMBL 36
Loading Target Snapshot...
Querying ChEMBL database. This may take a few seconds.
Target Snapshot

CHEMBL2120 Target Snapshot

Fibroblast growth factor 1 · SINGLE PROTEIN · Homo sapiens

Back to Search Search this target Browse approvals Evidence Card
125Compounds
13Assays
0Approved Drugs
115.0Activities
Free Research Context

Research home keeps recent targets

This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.

Research home Demo workspace
Navigation

Switch target

Move to another high-traffic target or paste a specific ChEMBL target ID.

Broader Open DB context

Frame the target before identity details

Structured disease, protein, and project context should read before the lower-level identity rail.

As of 2026-09-14

Fibroblast growth factor 1 shows late clinical disease relevance led by prostate cancer. 5 more disease programs remain visible in the same review block. 2 linked drugs keep the current disease frame grounded. Protein identity stays anchored to UniProt P05230. Start with prostate cancer, then reuse UniProt P05230 as the stable protein anchor across project notes and exports.

Review focus
Review-ready target frame

Start with prostate cancer, then reuse UniProt P05230 as the stable protein anchor across project notes and exports.

ChEMBL component mapping + Open Targets-ready proxy + ChEMBL 36 via Core Engine 2026-09-14 2 linked drugs
Open source guide
Disease program
prostate cancer

Fibroblast growth factor 1 shows late clinical disease relevance led by prostate cancer. 5 more disease programs remain visible in the same review block. 2 linked drugs remain visible in the same block.

Start review with prostate cancer because it currently carries late clinical support. Linked drugs include MUPARFOSTAT, SURAMIN HEXASODIUM. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Disease source · ChEMBL drug mechanism + indication proxy
Late clinical Open Targets-ready proxy 2 linked drugs
Open disease block
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Fibroblast growth factor 1 as ChEMBL target CHEMBL2120, mapped to UniProt P05230. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Fibroblast growth factor 1
SINGLE PROTEIN · Homo sapiens
As of 2026-09-14
ChEMBL target ID
CHEMBL2120
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-14
www.ebi.ac.uk
UniProt accession
P05230
Fibroblast growth factor 1
UniProt accession via ChEMBL component mapping As of 2026-09-14
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-14
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Source Guidance

Start with the right source

Choose the first block or source based on the question you are trying to answer.

Need stable target naming and protein identity?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Start here when your first question is whether Fibroblast growth factor 1 is the right protein anchor across sources, using UniProt P05230 as the stable mapping.

Jump to Protein Context
Need disease fit before discussing compounds?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use this block first when you need to confirm why prostate cancer is currently framed as late clinical support. It currently carries 2 linked drugs in the same disease frame.

Jump to Disease Context
Need a meeting-ready explanation of why this target matters?
Evidence Card
Review-ready rationale with source-aware context

Open the one-page evidence card when you want the rationale, activity base, and attribution together.

Open Review-ready Card
Overview

Basic Information

Verify identity, organism, and the fastest next research jumps from the same page.

Preferred NameFibroblast growth factor 1
Target TypeSINGLE PROTEIN
OrganismHomo sapiens
UniProtP05230
ChEMBL ↗ UniProt ↗ NCBI Protein ↗

Next Actions

SearchRun a focused querySearch the database using this target name as the starting context. ApprovalsCheck approved moleculesSee which approved drugs connect back to this target and its surrounding signal space. FeedScan papers & updatesStay in the project thread while checking recent papers and platform updates.
UniProt Context

UniProt Target Context

Reviewable protein naming and mapping context for this target snapshot.

Protein LabelFibroblast growth factor 1
UniProt AccessionP05230
Component TypeProtein
Sequence Length155 aa

Fibroblast growth factor 1

Source · UniProt accession via ChEMBL component mapping
UniProt Context ↗
Review Cue

How to read this target

Review this target as Fibroblast growth factor 1, mapped to UniProt P05230. Sequence length is 155 aa.

Mapped IDP05230
Review nameFibroblast growth factor 1
OrganismHomo sapiens
Disease Relevance

Disease Relevance & Evidence Level

Open Targets-ready disease context using the current target-indication evidence contract.

Late clinical Open Targets-ready proxy

Fibroblast growth factor 1 shows late clinical disease relevance led by prostate cancer. 5 more disease programs remain visible in the same review block.

Late clinical Phase III
prostate cancer
2 linked drugs · 2 direct · 2 efficacy
Linked drugMUPARFOSTAT
Linked drugSURAMIN HEXASODIUM
Late clinical Phase III
hepatocellular carcinoma
1 linked drug · 1 direct · 1 efficacy
Linked drugMUPARFOSTAT
Late clinical Phase III
Leishmaniasis
1 linked drug · 1 direct · 1 efficacy
Linked drugSURAMIN HEXASODIUM
Late clinical Phase III
trypanosomiasis
1 linked drug · 1 direct · 1 efficacy
Linked drugSURAMIN HEXASODIUM
Clinical signal Phase II
non-small cell lung carcinoma
2 linked drugs · 2 direct · 2 efficacy
Linked drugMUPARFOSTAT
Linked drugSURAMIN HEXASODIUM
Clinical signal Phase II
Acute kidney injury
1 linked drug · 1 direct · 1 efficacy
Linked drugSURAMIN HEXASODIUM
Source · ChEMBL drug mechanism + indication proxy
ChEMBL target record ↗
Review Cue

How to read disease relevance

Start review with prostate cancer because it currently carries late clinical support. Linked drugs include MUPARFOSTAT, SURAMIN HEXASODIUM. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Lead diseaseprostate cancer
Strongest levelLate clinical
Block modeOpen Targets-ready proxy
Assay Mix

Activity Type Distribution

IC502.0
KD113.0
Lead Set

Top Inhibitors (by pChEMBL)

ChEMBL IDpChEMBLTypeValue (nM)Phase
CHEMBL382044 9.92 Kd 0.12 Preclinical
CHEMBL198643 9.84 Kd 0.144 Preclinical
CHEMBL2059243 9.62 Kd 0.24 Preclinical
CHEMBL262707 9.41 Kd 0.39 Preclinical
CHEMBL2059242 9.36 Kd 0.44 Preclinical
CHEMBL2059241 9.22 Kd 0.6 Preclinical
CHEMBL265885 9.18 Kd 0.66 Preclinical
CHEMBL2059502 8.9 Kd 1.25 Preclinical
CHEMBL2059504 8.31 Kd 4.94 Preclinical
CHEMBL2303816 8.11 Kd 7.8 Preclinical
Distribution

pChEMBL Value Distribution

7
5.0
3
5.5
8
6.0
14
6.5
3
7.0
5
7.5
4
8.0
1
8.5
4
9.0
3
9.5
pChEMBL
Assay Landscape

Assay Landscape

13
Total Assays
107
Tested Compounds
1
Assay Types
Binding — 13 assays, 107 compounds
BAO Format Assays Compounds Avg pChEMBL
single protein format 12 106 6.5
assay format 1 1 5.0

Confidence Score Distribution

Source · ChEMBL 36 via Core Engine